Skip to main content

Table 5 Summary of serum AAB-003 pharmacokinetic parameters

From: First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

Parameters (units)

0.5 mg/kg (N = 6)

1 mg/kg (N = 6)

2 mg/kg (N = 16)

4 mg/kg (N = 17)

8 mg/kg (N = 24)

Cmax (μg/ml)

13.79 (48)

32.05 (33)

58.74 (21)

122.4 (14)

223.7 (28)

Tmax (hours)

1.92 (1.50, 6.05)

4.00 (2.17, 6.02)

1.54 (1.20, 2.12)

1.50 (1.00, 24.0)

3.02 (1.07, 6.00)

AUCinf (μg/hour/ml)

5597 (39)

13060 (18)

25270 (17)

46430 (21)

82140 (23)

t1/2 (days)

27.7 ± 6.99

20.04 ± 8.92

24.45 ± 4.87

21.10 ± 5.20

22.89 ± 4.51

CL (ml/hour/kg)

0.0893 (39)

0.0766 (18)

0.0791 (17)

0.0862 (21)

0.0974 (23)

Vss (ml/kg)

78.44 (38)

59.74 (37)

61.67 (21)

60.44 (26)

75.12 (27)

  1. N: Number of patients with pharmacokinetic parameters on day1 (may be different from number of patients with estimable t1/2). Geometric mean (geometric %CV) for all except median (range) for Tmax and arithmetic mean ± standard deviation for t1/2. AUC inf Total area under the concentration–time curve to infinity, CL Systemic clearance, C max Observed peak concentration, t 1/2 Apparent terminal phase elimination half-life, T max Time to peak concentration, Vss Steady-state volume of distribution
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193